RxDoctor Payments Data

Chintan Gandhi, MD

Hematology & Oncology · Tamarac, FLNPI 1568764629

Payments from drug & device makers

$556,953in general payments, 2019–2025

Across 263 payments — averaging $2117.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$234K
  • Daiichi Sankyo Inc.$92K
  • Regeneron$72K
  • Sanofi$66K
  • GSK$34K
  • Pfizer$34K
  • plus $25K from 24 others

What the payments were for

  • Food & beverage$1,46280%
  • Education$37220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$556,953 in reported general payments places this provider in the 80th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$966,344
Medicare patients
147
Services billed
54,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide78$1,049,653
PomalystPomalidomide30$689,411
SprycelDasatinib31$553,406
JakafiRuxolitinib Phosphate25$462,147
TagrissoOsimertinib Mesylate21$347,721
ImbruvicaIbrutinib20$329,013
ErleadaApalutamide17$254,601
VenclextaVenetoclax21$171,452
Abiraterone Acetate23$128,569
Dasatinib11$119,188
RetacritEpoetin Alfa-Epbx88$99,383
TasignaNilotinib Hcl11$68,742
EliquisApixaban52$30,648
XareltoRivaroxaban15$19,149
Ondansetron Hcl126$12,771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel$42$1,242,81761 claims
Incyte CorporationJakafi$23$462,14725 claims
AstraZenecaTagrisso$44$347,72121 claims
Johnson & JohnsonErleada, Xarelto$378$273,75032 claims
AbbVieVenclexta$380$171,45221 claims
PfizerRetacrit, Eliquis$33,773$130,031140 claims
NovartisTasigna$66$68,74211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Tamarac

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →